Safety and Efficacy of Drug Combinations Against Schistosomiasis

DBL -Institute for Health Research and Development650 enrolled

Overview

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

650

Conditions

Parasitic Diseases

Interventions

albendazole + praziquantelDRUG

albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)

mebendazole + praziquantelDRUG

mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)

Eligibility

Sex: ALLMin age: 1 YearMax age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Those with an age of 1-15 years of age * Are infected with schistosomiasis and soil-transmitted helminthiasis * Whose parent consent and who are willing to participate Exclusion Criteria: * Those with acute and chronic diseases other than schistosomiasis and soil-transmitted helminthiasis * Those with a history of any serious adverse drug reactions

Locations (1)

Vector Control Division

Kampala, Uganda

Outcomes

Primary Outcomes

Efficacy of treatment

Time frame: 6 weeks

Secondary Outcomes

Record of adverse reactions

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.